|
1
|
Gerecitano JF, Modi S, Rampal R, Drilon AE, Fury MG, Gounder MM, Harding JJ, Hyman DM, Varghese AM, Voss MH, France FO, Taldone T, Gomes DaGama E, Uddin M, Chiosis G, Lewis JS, Lyashchenko SK, Larson SM, Pressl C, Dunphy M. Phase I trial of the HSP-90 inhibitor PU-H71. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.2537] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Shanu Modi
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - Raajit Rampal
- Memorial Sloan Kettering Cancer Center, New York, NY
| | | | | | | | - James J. Harding
- Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY
| | | | | | | | | | - Tony Taldone
- Memorial Sloan Kettering Cancer Center, New York, NY
| | | | | | - Gabriela Chiosis
- Program in Molecular Pharmacology and Chemistry, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
| | | | | | | | | | - Mark Dunphy
- Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|